| Primary |
| Product Used For Unknown Indication |
53.1% |
| Herpes Zoster |
14.6% |
| Burkitt's Lymphoma |
3.2% |
| Herpes Virus Infection |
3.2% |
| Diffuse Large B-cell Lymphoma Stage Ii |
2.9% |
| Prophylaxis |
2.9% |
| Graft Versus Host Disease |
2.3% |
| Antibiotic Therapy |
1.7% |
| Herpes Simplex |
1.7% |
| Pain |
1.7% |
| Prophylaxis Against Graft Versus Host Disease |
1.7% |
| Ophthalmic Herpes Simplex |
1.5% |
| Retinitis Viral |
1.5% |
| Coronary Artery Disease |
1.2% |
| Encephalopathy |
1.2% |
| Evidence Based Treatment |
1.2% |
| Hiv Infection |
1.2% |
| Oral Herpes |
1.2% |
| Type 2 Diabetes Mellitus |
1.2% |
| Encephalitis |
0.9% |
|
| Renal Impairment |
19.5% |
| Vomiting |
7.8% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
6.5% |
| Drug Resistance |
6.5% |
| Neurotoxicity |
6.5% |
| Pain |
6.5% |
| Drug-induced Liver Injury |
3.9% |
| Hyponatraemia |
3.9% |
| Renal Failure Acute |
3.9% |
| Somnolence |
3.9% |
| Treatment Failure |
3.9% |
| Tremor |
3.9% |
| Urogenital Haemorrhage |
3.9% |
| Urticaria |
3.9% |
| Abdominal Pain Upper |
2.6% |
| Acute Generalised Exanthematous Pustulosis |
2.6% |
| Coeliac Disease |
2.6% |
| Fatigue |
2.6% |
| Hallucination |
2.6% |
| Herpes Zoster |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
37.6% |
| Prophylaxis |
7.0% |
| Chronic Lymphocytic Leukaemia |
6.1% |
| Herpes Zoster |
5.5% |
| Prophylaxis Against Graft Versus Host Disease |
4.7% |
| Infection Prophylaxis |
4.3% |
| Herpes Virus Infection |
4.1% |
| Infection |
4.1% |
| Pain |
3.8% |
| Pneumonia |
3.7% |
| Drug Use For Unknown Indication |
2.4% |
| Pyrexia |
2.4% |
| Foetal Exposure During Pregnancy |
2.3% |
| Bone Marrow Conditioning Regimen |
1.8% |
| Hiv Infection Cdc Category C3 |
1.8% |
| Burkitt's Lymphoma |
1.7% |
| Chemotherapy |
1.7% |
| Crohn's Disease |
1.7% |
| Small Intestine Transplant |
1.7% |
| Antifungal Prophylaxis |
1.4% |
|
| Renal Impairment |
11.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
10.0% |
| Drug-induced Liver Injury |
8.9% |
| Venoocclusive Liver Disease |
8.9% |
| Idiopathic Thrombocytopenic Purpura |
7.8% |
| Toxic Epidermal Necrolysis |
6.7% |
| Vomiting |
5.6% |
| Rectal Haemorrhage |
4.4% |
| Stevens-johnson Syndrome |
4.4% |
| Thrombocytopenia |
4.4% |
| Hallucination, Visual |
3.3% |
| Neutropenia |
3.3% |
| Renal Failure Acute |
3.3% |
| Status Epilepticus |
3.3% |
| Tremor |
3.3% |
| Acute Generalised Exanthematous Pustulosis |
2.2% |
| Cerebellar Syndrome |
2.2% |
| Cholestasis |
2.2% |
| Fatigue |
2.2% |
| Hepatitis |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.9% |
| Prophylaxis |
15.6% |
| Infection Prophylaxis |
8.4% |
| B-cell Lymphoma |
5.1% |
| Acute Myeloid Leukaemia |
4.6% |
| Bone Marrow Conditioning Regimen |
4.4% |
| Prophylaxis Against Graft Versus Host Disease |
4.4% |
| Plasma Cell Myeloma |
4.2% |
| Chronic Lymphocytic Leukaemia |
3.3% |
| Premedication |
2.9% |
| Hypertension |
2.7% |
| Aplastic Anaemia |
2.7% |
| Antiviral Prophylaxis |
2.6% |
| Antifungal Prophylaxis |
2.3% |
| Drug Use For Unknown Indication |
1.7% |
| Multiple Myeloma |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.7% |
| Diffuse Large B-cell Lymphoma |
1.4% |
| Pain |
1.4% |
| Infection |
1.2% |
|
| Sepsis |
11.3% |
| Febrile Neutropenia |
7.8% |
| Pyrexia |
7.8% |
| Vomiting |
6.7% |
| Thrombocytopenia |
6.4% |
| Pneumonia |
6.2% |
| Respiratory Failure |
6.2% |
| White Blood Cell Count Decreased |
5.6% |
| Neutropenic Sepsis |
4.8% |
| Staphylococcal Sepsis |
4.3% |
| Death |
3.5% |
| Neutropenia |
3.5% |
| Septic Shock |
3.5% |
| Urinary Tract Infection |
3.5% |
| Weight Increased |
3.5% |
| Platelet Count Increased |
3.2% |
| Pulmonary Embolism |
3.2% |
| Renal Failure Acute |
3.2% |
| Lung Infection |
2.9% |
| Rash |
2.9% |
|
| Interacting |
| Herpes Virus Infection |
26.7% |
| Herpes Zoster |
22.2% |
| Prophylaxis |
17.8% |
| Graft Versus Host Disease |
13.3% |
| Febrile Neutropenia |
4.4% |
| Aspergillosis |
2.2% |
| Cardiac Disorder |
2.2% |
| Depression |
2.2% |
| Epilepsy |
2.2% |
| Hiv Infection |
2.2% |
| Pain |
2.2% |
| Thrombosis Prophylaxis |
2.2% |
|
| Drug-induced Liver Injury |
54.5% |
| Urinary Incontinence |
18.2% |
| Drug Interaction |
9.1% |
| Liver Disorder |
9.1% |
| Somnolence |
9.1% |
|
